Linda Black

Dr. Black started with Gallant in 2019 and served as President and Chief Scientific Officer before moving to Chief Executive Officer in April 2021. She brings over 17 years of cross-functional experience leading strategic and operational initiatives in the biotechnology industry. She has led corporate development, finance, operations, and R&D along with a track record in regenerative medicine – with extensive experience in the development and commercialization of stem cell therapies for pets. From 2016 to 2019, she served as President and Chief Scientific Officer at Medicus Biosciences, a preclinical biotech firm focused on using polymer technologies for localized drug and stem cell delivery. Prior to Medicus, she served as the VP of Product Development for VetStem Biopharma, the first veterinary stem cell company to provide regenerative therapies to horses, dogs and cats. She authored the first peer reviewed publications describing the safety and efficacy of primary adipose-derived stem cells in osteoarthritis and muscle injury in working dogs. This culminated with leading a product development team to develop the first “off-the-shelf “stem cell therapies for dogs with osteoarthritis, which was later licensed to Aratana. She was the founder and CEO of SciStem Therapeutics, a company focused on delivering off-the-shelf genetically modified stem cells for bone healing in pets and people. Prior to those roles, Dr. Black consulted exclusively for Merial, Ltd, now Boehringer Ingelheim Animal Health, supporting R&D, marketing, and sales divisions. She is a member of the scientific advisory boards of Medicus Biosciences and Zander Therapeutics, and a member of the board of Directors for Gallant. Dr. Black holds a DVM from University of Wisconsin-Madison, a PhD in Cell and Molecular Biology from University of Pennsylvania School of Medicine, and completed her post-doctoral fellowship at GlaxoSmithKline.